Stent Applications for Palliative Treatment in Advanced Stage Esophageal Cancers

Basit Öğe Kaydı
dc.contributor.authorSenturk, Mustafa
dc.contributor.authorCakir, Murat
dc.contributor.authorYildirim, Mehmet Aykut
dc.contributor.authorKisi, Omer
dc.date.accessioned2024-02-23T14:26:38Z
dc.date.available2024-02-23T14:26:38Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractBackground and Aim. Endoscopic stenting is a generally safe and effective palliative treatment for esophageal malignancies. In this study, we aimed to present endoscopic stent applications, adverse events, and relative advantages of covered versus uncovered stents in our center. Methods. We examined cases of endoscopic stenting for palliative treatment of advanced stage esophageal cancers between January 2014 and July 2019. Age, gender, location of mass, adverse events, survival time, and stent type were evaluated. Outcomes of fully covered and uncovered self-expanding stents were compared with regard to adverse events, including stent migration and occlusion. Results. The mean age of the patients was 66.4 +/- 1, 52 were male, and 8 were female. Patients were followed up for a mean of 133 days. The most common complication due to stenting was migration. 13 patients developed adverse events. Migration was the most common adverse event, occurring in 8 (13%) patients. Although the migration rate of fully covered stents was higher than uncovered stents, there was no statistically significant difference (p=0.47). Stent occlusion was observed in 4 patients. In three cases, it was due to the tumor; an uncovered stent was placed again in these cases. Food-related occlusion developed in one patient. There was no statistical difference in terms of overall adverse event rate when comparing fully covered stents to uncovered stents (p=0.68). Conclusion. Endoscopic stenting is a viable palliative method with low morbidity and mortality in experienced centers. Though there are relative advantages with covered versus uncovered stents in individual cases, the overall adverse event rate is low and relatively similar.en_US
dc.identifier.doi10.1155/2021/8034948
dc.identifier.issn1687-6121
dc.identifier.issn1687-630X
dc.identifier.pmid34707656en_US
dc.identifier.scopus2-s2.0-85118528642en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1155/2021/8034948
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14258
dc.identifier.volume2021en_US
dc.identifier.wosWOS:000715820700002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHindawi Ltden_US
dc.relation.ispartofGastroenterology Research And Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[Keyword Not Available]en_US
dc.titleStent Applications for Palliative Treatment in Advanced Stage Esophageal Cancersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu